http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이봉은 ( Bong Eun Lee ),이태희 ( Tae Hee Lee ),김성은 ( Seong Eun Kim ),박경식 ( Kyung Sik Park ),박선영 ( Seon Young Park ),신정은 ( Jeong Eun Shin ),정기욱 ( Kee Wook Jung ),최석채 ( Suck Chei Choi ),홍경섭 ( Kyoung Sup Hong 대한내과학회 2015 대한내과학회지 Vol.88 No.1
Based on published guidelines on the management of chronic constipation, secondary causes should be excluded and then patientsshould be told to increase their dietary fiber intake to 20-25 g per day. If these measures do not improve the symptoms, conventionallaxatives are generally the next choice. Although there is limited evidence for the efficacy of these older laxatives due toa lack of well-designed clinical trials, most clinicians agree that they are effective at relieving the symptoms of constipation. Conventional laxatives include bulk-forming, osmotic, and stimulant laxatives. Bulking laxatives consist of fiber such as psyllium,cellulose, and bran. Osmotic laxatives are classified into sugar-based laxatives and polyethylene glycol. Bisacodyl and sodium picosulfateare stimulant laxatives. Understanding their mechanisms of action, efficacy, and side effects might improve the quality oflife of patients suffering from chronic constipation.
상부소화관운동 질환의 최신지견 : 위식도역류질환의 진단: 식도 및 식도 외 증상들
이봉은 ( Bong Eun Lee ),김광하 ( Gwang Ha Kim ) 대한내과학회 2010 대한내과학회지 Vol.78 No.2
The manifestations of gastroesophageal reflux disease (GERD) have been classified into either esophageal or extraesophageal symptoms. Esophageal manifestations include classic symptoms of reflux, such as heartburn and regurgitation, and atypical non-cardia
Laxatives 제대로 알기 ; 변비 약물 치료의 지침 - 어떤 약제를, 언제 사용해야 하는가?
신정은 ( Jeong Eun Shin ),홍경섭 ( Kyoung Sup Hong ),정기욱 ( Kee Wook Jung ),이태희 ( Tae Hee Lee ),이봉은 ( Bong Eun Lee ),박선영 ( Seon Young Park ),홍성노 ( Sung Noh Hong ),김성은 ( Seong Eun Kim ),박경식 ( Kyung Sik Park ) 대한내과학회 2015 대한내과학회지 Vol.88 No.1
To manage chronic constipation, dietary and lifestyle modifications should be tried before pharmacological intervention. Although there is no standardized treatment guideline for medical practice, the key considerations in the choice of laxative includethe treatment duration, dosing schedule, type of agent, effects and side effects of the agent, and cost. The first-line treatment is abulking or osmotic laxative. If the patient is still symptomatic, the physician can add or switch to other laxatives. Next, prucalopride,a highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist, could be considered. If the constipation is refractory tocombination therapy with conventional laxatives and prucalopride, patients should be referred for further evaluation, includingphysiological testing.
Laxatives 제대로 알기 ; 변비의 국소 치료: 관장과 좌약
김성은 ( Seong Eun Kim ),신정은 ( Jeong Eun Shin ),홍경섭 ( Kyoung Sup Hong ),이태희 ( Tae Hee Lee ),이봉은 ( Bong Eun Lee ),박선영 ( Seon Young Park ),홍성노 ( Sung Noh Hong ),정기욱 ( Kee Wook Jung ),박경식 ( Kyung Sik Park ) 대한내과학회 2015 대한내과학회지 Vol.88 No.1
The treatment for constipation should be individualized and dependent on the cause, coexisting morbidities, and patient’s cognitivestatus. Although most cases of constipation respond to conservative treatment, including dietary and life-style changes, or mildlaxatives, some patients still complain of consistent symptoms and need an assessment of defecatory dysfunction. There is insufficientevidence to support the use of enemas in chronic constipation, although many clinicians and patients find them useful andeffective for the treatment of fecal impaction when used with other modalities. In addition, suppositories can be considered as an initialtrial for the treatment of defecatory dysfunction, since they help to initiate or facilitate rectal evacuation. The routine use of enemasis typically discouraged, especially sodium phosphate enemas, although tap-water enemas seem safe for more regular use. Soapsuds enemas are not recommended due to possible rectal mucosal damage.
위장관 간질종양의 수술 후 재발한 환자에서 발생한 Imatinib의 부작용과 효능 - 증례와 문헌고찰
배정호,김광하,김동욱,이봉은,송근암,Jung Ho Bae,Gwang Ha Kim,Dong Uk Kim,Bong Eun Lee,Geun Am Song 대한소화기암연구학회 2013 Journal of digestive cancer reports Vol.1 No.2
A 79-year-old man was diagnosed with gastrointestinal stromal tumor (GIST) of the gastric cardia. We performed proximal subtotal gastrectomy and started imatinib therapy as adjuvant treatment after surgery. Whole body skin rash with urticaria was onset on 10 days after imatinib treatment, and the patient decided to stop imatinib because of side effect. After 3 months, PET CT revealed GIST was recurred at spleen and abdominal lymph nodes, abdominal wall. The patient was then restarted on imatinib therapy. On follow-up imaging studies, the tumor almost disappeared, but both pleural effusion and pericardial effusion were found. In this paper, we describe a case of clinical course and side effects in recurred GIST after adjuvant imatinib mesylate treatment.
진행성 췌장암을 가진 노인환자에서 Gemcitabine 항암화학요법의 안정성과 효과 - 노인에서 Gemcitabine의 안정성 -
최유이,김동욱,정재훈,이봉은,김광하,송근암,You Ie Choi,Dong Uk Kim,Jae Hoon Cheong,Bong Eun Lee,Gwang Ha Kim,Geun Am Song 대한소화기암연구학회 2013 Journal of digestive cancer reports Vol.1 No.1
Background/Aims: Gemcitabine is regarded as a reference regimen for advanced pancreatic cancer and shows relatively safe toxicity profiles compared with other cytotoxic agents. However, many oncologists are appeared to be still reluctant to treat elderly pancreatic cancer patients with cytotoxic chemotherapy because of predicted low response rate and potential adverse events. Methods: All patients who were received gemcitabine based chemotherapy between 2007 and 2010 were identified and clinical, laboratory, radiographic data were retrospectively reviewed. Patients were divided into two groups based on their ages: less than 65, and equal or more than 65 years old. Gemcitabine, at a dose of 1,000 mg per square meter of body surface area, was administered by intravenously over 30 minutes weekly for 3 weeks followed by 1 week rest, alone or along with other chemotherapeutic agents including cisplatin, capecitabine and erlotinib. Results: A total of 61 patients were identified and all patients were not eligible to receive operation because of advanced stage at diagnosis. Twenty three patients (37.7%) were equal or more than 65 year of age. Mean age was 56 years old and 71 years old in each group. Laboratory data including CA 19-9 were not significantly different. More gemcitabine monotherapy was delivered (56.5% vs. 26.3%, p=0.029) and less second or third line therapy was adminis- tered (17.4% vs. 50.0%, p=0.014) in elderly group. Cholangitis occurred and stent placement were performed similarly in both groups. Conclusion: Gemcitabine based chemotherapy can be administered safely to elderly pancreatic cancer patients and comparable response rate and progression free survival can be expected as young patients.
수술과 항암치료 후 종양표지자 검사의 상승으로 복막 가성점액종의 재발을 확인한 1례
한인섭,송근암,김광하,이봉은,백동훈,이성준,이문원,한성용,In Sub Han,Geun Am Song,Kwang Ha Kim,Bong Eun Lee,Dong Hoon Baek,Seong Jun Lee,Moon Won Lee,Sung Yong Han 대한소화기암연구학회 2016 Journal of digestive cancer reports Vol.4 No.1
Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by profuse jelatinous materials in the abdominal cavity and pelvis with mucinous implants on the peritoneal surface. There are some studies for serum tumor markers, including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125), to assess the risk of recurrence following cytoreductive surgery and intraperitoneal chemotherapy. However, rare cases were reported about recurrence with increasing serum CEA levels. Herein, we report a case of recurrence of PMP according to serially elevated serum CEA.
장결핵과 크론병의 감별 진단에 있어서 체외 Interferon-γ 검사의 유용성
이정남 ( Jung Nam Lee ),류동엽 ( Dong Yup Ryu ),박성한 ( Sung Han Park ),유현석 ( Hyun Seok You ),이봉은 ( Bong Eun Lee ),김동욱 ( Dong Uk Kim ),김태오 ( Tae Oh Kim ),허정 ( Jeong Heo ),김광하 ( Gwang Ha Kim ),송근암 ( Geun Am So 대한소화기학회 2010 대한소화기학회지 Vol.55 No.6
목적: 소화기 증상과 대장 또는 회맹부 궤양을 보이는 환자에서 장결핵과 크론병을 임상 소견 및 내시경 소견만으로 구분하는 것은 어렵다. 이번 연구에서는 장결핵과 크론병의 감별을 위한 체외 interferon-γ (INF-γ) 검사의 유용성을 알아보고자 하였다. 대상 및 방법: 이번 연구는 2007년 1월부터 2009년 1월까지 장결핵과 크론병의 감별 진단이 어려웠던 60명을 대상으로 하였다. ESAT-6과 CFP-10에 반응하여 INF-γ을 생산하는 T 림프구를 측정하는 T-SPOT.TB 검사를 시행하였으며 최종 진단과 비교하여 T-SPOT.TB 검사의 유용성을 평가하였다. 결과: T-SPOT.TB 검사 결과 양성이20명, 음성이 40명이었다. 장결핵으로 확진된 12명의 환자는 T-SPOT.TB 검사가 모두 양성이었고, 기타 6명의 크론병환자와 2명의 베체트장염 환자에서 T-SPOT.TB 검사가 양성이었다. T-SPOT.TB 검사가 음성인 40명 중 크론병 38명, 베체트장염과 비특이 장염이 각각 1명이었고 장결핵은 없었다. T-SPOT.TB 검사의 장결핵 진단에 대한 민감도는 100%, 특이도는 83.3%, 양성 예측도는 60.0%, 음성 예측도는 100%였다. 결론: 장결핵과 크론병의 감별 진단이 어려운 경우에 T-SPOT.TB 검사는 음성일 경우 장결핵을 배제할 수 있는 신속한 검사로 생각한다. 향후 T-SPOT.TB 검사의 장결핵과 크론병 감별 진단에의 유용성을 확인하기 위해 대규모 전향 연구가 필요하다. Background/Aims: It is difficult to clinically and endoscopically differentiate intestinal tuberculosis (ITB) and Crohn`s disease (CD). The aim of this study was to evaluate the usefulness of in vitro interferon-gamma (INF-γ) assay for differential diagnosis between ITB and CD. Methods: Sixty patients for whom differential diagnosis between ITB and CD was difficult were enrolled between January 2007 and January 2009. The INF-γ-producing T-cell response to early secreted antigenic target 6 and culture filtrate protein 10 were measured by T-SPOT.TB blood test in vitro. We evaluated the usefulness of T-SPOT.TB blood test by comparing its results with the final diagnosis. Results: Twenty and forty patients were revealed to be positive and negative in T-SPOT.TB blood test, respectively. Of the 20 patients found to be positive, 12 patients (60%) were finally diagnosed as ITB, 6 patients as CD, and 2 patients as Behcet`s enterocolitis. Of the 40 patients with negative results, 38 patients (95%) were diagnosed as CD; one as Behcet`s enterocolitis; one as nonspecific colitis; none as ITB. The sensitivity and specificity of T-SPOT.TB blood test for ITB were 100% and 83.3%, respectively. Positive and negative predictive values of T-SPOT.TB blood test for ITB were 60.0% and 100%, respectively. Conclusions: When differential diagnosis between ITB and CD is difficult, T-SPOT.TB blood test may be a helpful and rapid diagnostic tool to exclude ITB. Prospective large-scaled studies are required for further evaluation of the usefulness of T-SPOT.TB blood test for differential diagnosis between ITB and CD. (Korean J Gastroenterol 2010;55:376- 383)